• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

MBI restructures to focus on US contrast

Article

Ultrasound contrast developer Molecular Biosystems has let go 25% of its staff and eliminatednon-ultrasound R&D programs in an effort to cut expenses.The San Diego firm, which developed the echocardiography agentAlbunex, said the move should save $6

Ultrasound contrast developer Molecular Biosystems has let go 25% of its staff and eliminatednon-ultrasound R&D programs in an effort to cut expenses.The San Diego firm, which developed the echocardiography agentAlbunex, said the move should save $6 million annually. MBI'sstock fell 23% to $7 a share on the news.

MBI last week said it terminated 48 employees from its 197-personwork force and discontinued R&D for MRI and CT agents. MBIwill continue developing Oralex, a gastrointestinal oral ultrasoundagent in phase-one trials, and FS069, a second-generation myocardialperfusion agent awaiting Food and Drug Administration approvalto begin phase-one studies (SCAN 7/27/94).

Earlier last month, MBI posted results for its third quarterof 1995 (end-December). The company recorded a net loss for thequarter of $2.2 million, compared to a net loss of $1.1 millionin the same period a year ago. MBI's revenues were $6.9 million,compared to $5.5 million in the third quarter of 1993. MBI's marketingpartner Mallinckrodt Medical began selling Albunex in the U.S.in October (SCAN 8/31/94).

Related Videos
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Related Content
© 2024 MJH Life Sciences

All rights reserved.